COLL · Collegium Pharmaceutical Inc
United States · RS rating 19 · As of 2026-10-14
| Price | 22.51 USD |
|---|---|
| 1-day change | +4.5% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 85 / 8 / 22 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 12 / 22 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | -45.2% |
| Sales growth Q/Q | -1.9% |
| Distance from 52-week high | +54.8% |
| Market cap (USD) | $1.0B |